TABLE 3.
Most common a TEAEs (any grade) in Chinese patients with relapsed/refractory B‐cell malignancies receiving zanubrutinib
| Preferred term, n (%) | 160 mg BID, (n = 34) | 320 mg QD, (n = 10) | Total (N = 44) |
|---|---|---|---|
| Patients with ≥1 any‐grade TEAE | 33 (97.1) | 10 (100.0) | 43 (97.7) |
| Neutrophil count decreased | 17 (50.0) | 7 (70.0) | 24 (54.5) |
| Anaemia | 12 (35.3) | 4 (40.0) | 16 (36.4) |
| Upper respiratory tract infection | 10 (29.4) | 5 (50.0) | 15 (34.1) |
| White blood cell count decreased | 11 (32.4) | 3 (30.0) | 14 (31.8) |
| Platelet count decreased | 8 (23.5) | 2 (20.0) | 10 (22.7) |
| Rash | 8 (23.5) | 2 (20.0) | 10 (22.7) |
| Hematuria | 6 (17.6) | 3 (30.0) | 9 (20.5) |
| Hyperuricemia | 6 (17.6) | 3 (30.0) | 9 (20.5) |
| Pneumonia | 6 (17.6) | 3 (30.0) | 9 (20.5) |
| Cough | 5 (14.7) | 3 (30.0) | 8 (18.2) |
| Weight increased | 5 (14.7) | 3 (30.0) | 8 (18.2) |
Abbreviations: BID, twice daily; QD, once daily; TEAE, treatment‐emergent adverse event.
a
Occurring in ≥15% of patients overall.